🐦 推特Wall St EngineCodex · 实盘不做把握 5/10
北京时间·🕒 发布 04:05:32时区推断·⟳ 抓取 04:06:08·⚡ 决策 08-04 13:20:30 +9h14m·84.2 天前
Vertex公布2026年二季度业绩，收入小幅超预期并上调全年收入指引但EPS基本不超预期
Vertex二季度收入33.3亿美元高于市场预期32.3亿美元，全年收入指引上调至131亿-132亿美元，但上修幅度相对其大市值有限。
📄 原文Wall St Engine@wallstengine↗ 原文
VERTEX $VRTX Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $3.33B (Est. $3.23B) 🟢; +12% YoY 🔹 Adj. EPS: $4.73 (Est. $4.73) 🟡 🔹 C…
不做 Vertex Pharmaceuticals（VRTX.US）
财报为收入小幅超预期和指引小幅上调，但EPS无明确超预期、非CF收入指引不变且盘后反应偏弱；对大市值主标的缺少足够短线edge，不做。
不做 CRISPR Therapeutics（CRSP.US）
CASGEVY增长对CRSP方向偏正，但本次只是Vertex财报中的已跟踪商业化数据，按40%经济权益读穿后的增量相对亏损和市值仍不够强，等待CRSP自身财报或更明确商业化上修。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Vertex此前公告将在2026-08-03美股盘后公布二季度业绩并召开电话会，确认事件发生窗口。
- 社交快讯汇总Vertex Q2收入、EPS、CASGEVY/JOURNAVX销售和全年收入指引上调。
- 媒体确认收入33.3亿美元、全年收入指引上调至131亿-132亿美元，但指出调整后EPS略低于预期且股价盘后小幅下跌。市场反应:VRTX盘后小幅下跌，未形成正向确认。
关键理由
- Vertex二季度收入33.3亿美元高于市场预期32.3亿美元，全年收入指引上调至131亿-132亿美元，但上修幅度相对其大市值有限。
- 调整后EPS为4.73美元，基本等于或略低于市场预期，财报不是明确的盈利超预期事件。
- CASGEVY收入7640万美元、环比Q1的4300万美元继续增长；CRISPR享有CASGEVY约40%项目经济权益，但该收入增量相对CRSP亏损规模和股价波动不足以单独形成高胜率隔夜追多。
主要风险
- VRTX盘后已有媒体称股价小幅下跌，说明市场没有把这份财报当成明确正向重定价。
- CASGEVY/JOURNAVX增长仍处商业化早期，全年非CF收入指引维持5亿美元以上不变，缺少新的上修惊喜。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-04 · 影响 weakens
Investor's Business Daily称收入指引上调但EPS略低于预期，VRTX盘后小幅下跌。
检索:Vertex Q2 2026 earnings shares dip EPS miss revenue guidance 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-05-04 · 影响 weakens
CRISPR Q1披露CASGEVY收入4300万美元且净亏损1.229亿美元，本次约3300万美元的环比收入增量按40%经济权益读穿后不足以覆盖亏损基数。
检索:CRISPR Therapeutics CASGEVY Q1 2026 revenue collaboration expense net loss 原文 ↗
原文全文
展开原文 · 1,278 字
VERTEX $VRTX Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $3.33B (Est. $3.23B) 🟢; +12% YoY
🔹 Adj. EPS: $4.73 (Est. $4.73) 🟡
🔹 CASGEVY Revenue: $76M; +151% YoY
🔹 JOURNAVX Revenue: $50M; +317% YoY
Raises FY26 Guide:
🔹 Revenue: $13.1B-$13.2B (Est. $13.06B) 🟢
🔹 Prior Revenue Guide: $12.95B-$13.1B
🔹 Non-CF Revenue: $500M+; unchanged
🔹 GAAP R&D/SG&A Exp.: $6.3B-$6.45B; unchanged
🔹 Non-GAAP R&D/SG&A Exp.: $5.65B-$5.75B; unchanged
🔹 Non-GAAP Tax Rate: 19.5%-20.5%; unchanged
Product Revenue:
🔹 TRIKAFTA/KAFTRIO: $2.50B
🔹 ALYFTREK: $573.6M
🔹 CASGEVY: $76.4M; +151% YoY
🔹 JOURNAVX: $49.6M
Other Q2 Metrics:
🔹 U.S. Revenue: $2.06B; +11% YoY
🔹 Ex-U.S. Revenue: $1.28B; +14% YoY
🔹 GAAP Net Income: $1.1B; vs $1.0B LY
🔹 Cash & Marketable Securities: $13.6B; vs $12.3B LY
Comments:
🔸 “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pillar, further diversifying our portfolio.”
🔸 “With this breadth of commercial and clinical opportunities, we look forward to bringing more medicines to more patients around the globe and in so doing, creating long-term value.”
🔹 Revenue: $3.33B (Est. $3.23B) 🟢; +12% YoY
🔹 Adj. EPS: $4.73 (Est. $4.73) 🟡
🔹 CASGEVY Revenue: $76M; +151% YoY
🔹 JOURNAVX Revenue: $50M; +317% YoY
Raises FY26 Guide:
🔹 Revenue: $13.1B-$13.2B (Est. $13.06B) 🟢
🔹 Prior Revenue Guide: $12.95B-$13.1B
🔹 Non-CF Revenue: $500M+; unchanged
🔹 GAAP R&D/SG&A Exp.: $6.3B-$6.45B; unchanged
🔹 Non-GAAP R&D/SG&A Exp.: $5.65B-$5.75B; unchanged
🔹 Non-GAAP Tax Rate: 19.5%-20.5%; unchanged
Product Revenue:
🔹 TRIKAFTA/KAFTRIO: $2.50B
🔹 ALYFTREK: $573.6M
🔹 CASGEVY: $76.4M; +151% YoY
🔹 JOURNAVX: $49.6M
Other Q2 Metrics:
🔹 U.S. Revenue: $2.06B; +11% YoY
🔹 Ex-U.S. Revenue: $1.28B; +14% YoY
🔹 GAAP Net Income: $1.1B; vs $1.0B LY
🔹 Cash & Marketable Securities: $13.6B; vs $12.3B LY
Comments:
🔸 “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pillar, further diversifying our portfolio.”
🔸 “With this breadth of commercial and clinical opportunities, we look forward to bringing more medicines to more patients around the globe and in so doing, creating long-term value.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。